Q2 Return: +7%
YTD Return: +14%
Investor: Rick Pendergraft
Mylan (MYL) is proof that sometimes, slow and steady is the way to go. The stock was hanging around in sixth place at the end of the first quarter with a decent 5% climb.
Unlike some of the previous picks, though, it actually kept on climbing. In fact, Mylan’s total return is just behind the broader market’s — and that’s good enough for a fourth-place halftime finish.
The pharma company — chosen by Rick Pendergraft for its strong technicals and fundamentals — gained momentum in early May after reporting a 19% year-over-year improvement in earnings and maintained its outlook. It also has made more recent headlines for launching a generic version of Viagra in 11 European countries.
If the good news keeps coming, Pendergraft might just be proved correct in his hypothesis of 30% upside.
Halfway through the year, he’s basically halfway there.